SecBot SecBot
S-3 ·Filed Aug 7, 2026

AGEN

AGENUS INC
BEARISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001193125-26-340213
Shelf registration, potential dilution
Actionable Insight ▼ Bearish

The massive registered share count (173% of outstanding) creates severe overhang risk, though much is tied up by 4.99%-9.99% beneficial ownership blockers on the warrants. Watch for 424B prospectus supplements signaling actual sales by large holders (Commodore Capital, RA Capital, TCG Crossover), any reduction in ownership caps via 61-day notice would accelerate selling. The $85M PIPE proceeds should extend runway but with Q1 2026 cash of only $35M (after Q2 2026 $34.5M revenue, largely non-cash), capital needs remain acute.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

AGEN drug pipeline →

botensilimab

◆ Mixed Named in this S-3
Impact
Phase
Phase 3
Time to market
At least 3-5 years if Phase 3 BATTMAN succeeds; accelerated approval pathway was denied by FDA
Next catalyst
None dated

What to watchAgenus just announced a heavily dilutive ~$85M PIPE at $3.69/share to fund the Phase 3 BATTMAN trial, the stock is likely to trade under pressure from the overhang. Near-term upside depends on Phase 2 data catalysts (ASCO/ESMO presentations) and potential partnership deals, not regulatory approvals. The ~14.4% short interest adds squeeze risk on positive data surprises, but the fundamental path to commercialization is years away.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.00
T+0 close · Aug 7, 2026 · via day close
Latest settled
−3.43%
T+60 · $6.76
Vs SPY
−1.53%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 10 $7.00entry
  2. T+1 · 3mo ago −2.43%α −2.11% · $6.83
  3. T+5 · 3mo ago +2.14%α +2.19% · $7.15
  4. T+20 · 2mo ago +10.87%α +11.78% · $7.76
  5. T+60 · 14d ago −3.43%α −1.53% · $6.76
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Agenus filed a resale registration statement on Form S-3 to register up to 77,976,718 shares of common stock held by selling securityholders from its July 2026 $85M private placement. The filing is a contractual obligation under the Registration Rights Agreement and does not represent a new primary offering, Agenus receives no proceeds from the resale but could receive up to $255M if warrants are exercised for cash. With a $335M market cap, the registered shares represent over 170% of current outstanding shares, creating massive near-term overhang risk even though most warrants are subject to beneficial ownership limitations.

Key Facts

  • Registers 77,976,718 shares for resale by selling securityholders, including 1,626,015 issued shares, 21,409,212 pre-funded warrant shares, and 54,941,491 purchase warrant shares
  • Registered under Registration Rights Agreement from July 13, 2026 $85M private placement (closed July 15, 2026)
  • Agenus receives no proceeds from resale; would receive cash only if warrants exercised, Series A ($4.02 strike) and Series B ($5.03 strike) warrants could yield up to $255M if fully exercised
  • Current shares outstanding: 45,009,670 as of July 31, 2026, registered shares equal ~173% of outstanding
  • Stock closed at $7.49 on August 6, 2026; Series A and B warrants are in-the-money by $3.47 and $2.46 respectively
  • KPMG audit report included a going-concern explanatory paragraph for FY2025 financials

Financial Impact

Max potential warrant exercise proceeds of $255M; registration covers $607.8M in market value of shares at $7.795 reference price

dilutionshare count

Risk Factors

  • Massive potential dilution, registered shares equal ~173% of current outstanding, even with most warrants subject to beneficial ownership caps
  • Selling pressure from institutional holders (Commodore Capital, RA Capital, Invus, Ligand, TCG Crossover) who obtained shares at a combined $3.69/unit, now 103% above cost at $7.49
  • Going concern risk highlighted by KPMG; pre-revenue clinical-stage company with cash burn and uncertain Phase 3 trial outcomes
  • BATTMAN trial terminated due to funding prioritization, narrowing pipeline to botensilimab/balstilimab ROBBIN trial

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001193125-26-340213
Document: d120245dexfilingfees.htm0001193125-26-340213
Document: d120245dex51.htm0001193125-26-340213
Document: d120245dex232.htm0001193125-26-340213
Document: 0001193125-26-340213-index-headers.html0001193125-26-340213
Document: 0001193125-26-340213-index.html0001193125-26-340213
Document: 0001193125-26-340213.txt0001193125-26-340213

Track record

12 reports on AGEN

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +138.65% at T+60 after the May 11, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
  2. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $6.97 Now $6.29 −9.76% settles Feb 12
  3. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $6.44 Now $6.29 −2.33% settles Feb 3
  4. Aug 12, 202613w ago 8-K Neutral 2/10 Entry $7.00 to $6.90 Now $6.29 −10.14% ▼ −1.43% +3.81% vs SPY
  5. Aug 12, 202613w ago Institutional Cluster Mixed 4/10 Entry $6.90 to $6.97 Now $6.29 −8.84% ▲ +1.01% +5.89% vs SPY
  6. Aug 7, 202614w ago S-3 Bearish 7/10 Viewing Entry $7.00 to $6.76 Now $6.29 +10.14% ▲ +3.43% +1.53% vs SPY
  7. Aug 6, 202614w ago 8-K Neutral 5/10 Entry $7.49 to $6.84 Now $6.29 −16.02% ▼ −8.68% −7.01% vs SPY
  8. Jul 17, 202617w ago S-3 Bearish 5/10 Entry $4.97 to $6.95 Now $6.29 −26.56% ▼ −39.84% −35.00% vs SPY
  9. Jul 13, 202618w ago 8-K Bearish 6/10 Entry $6.12 to $7.49 Now $6.29 −2.78% ▼ −22.39% −18.39% vs SPY
  10. May 13, 202626w ago DEFA14A Neutral 4/10 Entry $3.47 to $6.96 Now $6.29 +81.27% ▲ +100.58% +96.14% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Wed (10h 24m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 7, 2026